Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

Drugmaker Eli Lilly says that approval of its experimental Alzheimer’s medication donanemab will be delayed beyond the end of March as the US Food and Drug Administration plans to call a last ...

Experimental Eli Lilly Alzheimer’s drug donanemab is being readied for an FDA submission along the same regulatory path the agency used to approve Biogen’s Aduhelm. Though the Lilly drug met ...

If approved, Eli Lilly's drug would become the second Alzheimer's drug of its kind currently on the U.S. market after another treatment called Leqembi from Biogen and Eisai.

Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March as the U.S. Food and Drug Administration plans to call a last ...

A second drug that modestly slows the progression of Alzheimer’s disease could be approved by the end of this year, manufacturer Eli Lilly said Monday. In a statement, Lilly said it applied to ...

Eli Lilly (NYSE: LLY) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA). The new drug, Kisunla, has ...

Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March as the U.S. Food and Drug Administration plans to call a last ...

Eli Lilly (LLY-4.22%) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA).

Eli Lilly said Thursday that it is nearly ready to take another shot at getting regulatory approval for a possible Alzheimer’s drug.The drugmaker plans to submit its potential treatment ...